Teva collaborating with Israeli academia on next-gen cancer antibodies

Teva collaborating with Israeli academia on next-gen cancer antibodies
Dr Hafrun Fridriksdottir with Prof. Daniel Zajfman (credit: Eyal Tuag)

Teva Pharmaceuticals has signed a collaboration agreement with the commercial arm of the Weizmann Institute of Science to identify the next generation of innovative antibodies for cancer treatment.

The collaboration with the Yeda Research and Development Company follows an exhaustive process conducted by Teva to identify and engage in strategic collaborations with leading research teams at Israeli universities.

The team will be led by Dr Rony Dahan, a leading researcher in antibody and cancer immunology and immunotherapy studies, who joined the Weizmann Institute of Science two years ago after completing postdoctoral research at Rockefeller University.

Dr. Dahan and other leading researchers at Weizmann will work together with research teams at Teva, both in Israel and globally, to incorporate a number of research fields and groups that will focus on advanced immunological research, computational biology and advanced single-cell analysis capabilities.

“The decision to enhance collaboration with Israeli academia is due to the outstanding knowledge and innovation that characterise these institutions and its researchers, who are among the most talented worldwide,” said Dr Hafrun Fridriksdottir, Teva’s Executive Vice President of Global R&D.

Prof. Daniel Zajfman, President of the Weizmann Institute of Science, added: “This is very good news to the academy, the researches and the industry in Israel. There’s no doubt that this long-term investment will bear fruits and lead to breakthroughs in science and technology.”